Latest News

FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.

FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.

FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.

If approved, ecopipam would be the first new therapy indicated for pediatric patients with Tourette syndrome in more than 10 years.

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

Relationship-based navigation helped more primary care patients access health and social services than referral to a free information service.